We initiated the systematic profiling of the dorsolateral prefrontal cortex obtained from a subset of autopsied individuals enrolled in the Religious Orders Study (ROS) or the Rush Memory and Aging Project (MAP), which are jointly designed and belong to a very few prospective studies of aging and dementia with detailed, longitudinal cognitive phenotyping during life and a quantitative, structured neuropathologic examination after death for >3,322 subjects. Here, we outline the first generation of data including genomewide genotypes (n=2,090), whole genome sequencing (n=1,179), DNA methylation (n=740), chromatin immunoprecipitation with sequencing using an anti-Histone 3 Lysine 9 acetylation (H3K9Ac) antibody (n=712), RNA sequencing (n=638), and miRNA profile (n=702). Generation of other omic data including ATACseq, proteomic and metabolomics profiles is ongoing. Thanks to its prospective design and recruitment of older, non-demented individuals, these data can be repurposed to investigate a large number of syndromic and quantitative neuroscience phenotypes. The many subjects that are cognitively non-impaired at death also offer insights into the biology of the human brain in older non-impaired individuals.
model to estimate person-specific annual rates of cognitive decline controlling for known confounders such as demographics and years of education. The approach used in constructing these traits is described in detail elsewhere 1, 2 and can be applied to specific cognitive domains, e.g., episodic memory decline, one of the hallmarks of AD. In addition, cognitive and pathologic data can be integrated to generate new traits that capture the difference between observed cognitive function and the extent of neuropathologies present in each individual's brain: for example, previous studies have generated measures of residual cognitive decline 3 or residual cognition, after accounting for a participant's neuropathologic burden 4 .
Cataloguing the multi-omic data of the neuronal cells in all the ROSMAP subjects regardless of their disease trajectory can provide insight to the molecular events that contribute to aging-related cognitive decline. We generated complementary sets of data from the dorsolateral prefrontal cortex (DLPFC) of individuals in the study after their death. All available brains at the time of funding were used in each omic generation from the DLPFC. Selection of subjects for genome-wide genotyping was different as that was performed from all self-reported non-Latino whites. Whole genome sequencing was limited to subjects with autopsy data. The data described in this report represent data that exist today and are available on Synapse. Numerous additional layers of data, including proteomic and metaboloimc data, from tissue samples and purified cell populations are being produced and will become available as the data are finalized. We look forward to this large set of molecular and phenotypic data being repurposed by the neuroscience and other communities of researchers.
Methods

The Religious order Study and the Memory and Aging Project (ROSMAP)
The ROS and MAP cohorts have been designed for data and sample sharing, and they have been at the forefront of large-scale omic data generation from the human brain and also of sharing such data through efforts such as the DREAM challenge 5 and the AMP-AD research program funded by the National Institute of Aging. Previous reports described the study design and data collection scheme of each study in detail 6, 7 . By October 8, 2017, 3,322 ROSMAP participants (72.7% females) were enrolled and completed the baseline assessment, of which 1,702 (67.3% females) had died and 1,475 (67.2% females) had undergone brain autopsies. The autopsy rate in these studies exceeds 86%, ensuring that the autopsied subjects are representative of the study populations. Tables 1 and 2 outline the demographic and selected diagnostic characteristics of the subjects included for each set of data; they also list the most commonly used phenotypes. Figure 1 illustrates the extent of subject overlap among the different sets of data.
Phenotypic data is accruing continually in ROS and MAP, and new phenotypes are periodically added to the routine clinical and pathological data collection. Thus, these new phenotypes become available as additional neuropathologic and other characterizations are performed. The ante-mortem and neuropathologic traits that are currently available can be browsed to assemble biological sample sets and data sets with the features desired by the investigator through the RADC Research Resource Sharing Hub (https://www.radc.rush.edu/;jsessionid=8D1CD9FBE972335E0DD0494972E83B2A).
The high-dimensional data described in this manuscript can be obtained through the Accelerating Medicnes Partnership for Alzheimer's disease (AMP-AD) Knowledge Portal that is supported by the National Institute of Aging (https://www.synapse.org/ampad). The phenotypes listed in Table 2 are available through this portal, and additional phenotypic data are available from RADC. Table 3 outlines the data through the portal. Additional data are being produced and will be available through the portal as they complete quality control analyses.
An important element of the design of the ROS and MAP studies is that all individuals are without known dementia at the time of entry into the study. Their cognitive trajectory is captured using a detailed battery of neuropsychological tests that is deployed annually to all living subjects. Subjects are also evaluated neurologically every year, and, at the time of death, a review of all ante-mortem data leads to a final clinical diagnosis for each participant: each individual receives a diagnosis of syndromic Alzheimer's disease (AD), of mild cognitive impairment (MCI), or of being cognitively non-impaired (NCI). After the autopsy is concluded, a spectrum of neuropathologic diagnoses are obtained, such as a pathologic diagnosis of AD as defined using the modified NIA Reagan criteria 8 .
However, many other pathologies are present in the brains of older individuals (the mean age of death is 88.8 years old in ROSMAP), and they are catalogued for each participant.
As shown by Figure 2 , there are imperfect overlaps of the two types of AD diagnoses.
There are 95 participants with clinical AD without a pathological AD diagnosis, while
Molecular data generation
The RADC maintains a sample archive that contains DNA samples from each subject as well as the brains of deceased ROS subjects and the brain, spinal cord, selected muscles and nerves of MAP subjects. One hemisphere is cut into coronal slabs and frozen; the other hemisphere is fixed in 4% paraformaldehyde. Samples can be requested through the RADC website (www.radc.rush.edu).
Genotype data
DNA used for genotyping ROS and MAP participants was collected from postmortem brain tissue, whole blood, or lymphocytes. The majority of samples were genotyped on the Affymetrix GeneChip 6.0 platform (Santa Clara, CA, USA) at the Broad Institute's Center for Genotyping (n=1204) or the Translational Genomics Research Institute (n=674). Additionally, 566 participants were genotyped on the Illumina OmniQuad Express platform at Children's Hospital of Philadelphia. The same QC protocol was applied to all datasets using PLINK 9 (pngu.mgh.harvard.edu/purcell/plink). We have limited analyses to participants of European decent. On the SNP level, we applied the following quality control (QC) filters: a genotype call rate > 95%, MAF > 0.01, misshap test 1x10 -9 , and a Hardy-Weinberg p < 0.001. The EIGENSTRAT software was used to calculate principle components used to control for population sub-structure; the top three principal components (PC)s are sufficient to correct for residual stratification. 10 The final QC'ed dataset consists of 1709 participants of European ancestry from the Affy 6.0 platform and 384 participants from the Illumina platform. Using Beagle software (version: 3.3.2) and the 1000 Genomes Project (2011, Phase 1b data freeze) as a reference, dosage data was imputed on > 35 million SNPs for all genotyped samples who passed QC. We performed imputation separately for each genotyping platform. After removing SNPs with a MAF < 0.01 or an imputation quality info score < 0.3, approximately 7.5 million SNPs remained to analyze. Further information regarding genotyping and imputation can be found in previous publications. 11, 12 Following substantial improvements in phasing software and haplotype reference panels 
RNA Sample Preparation
Approximately 100 mg of gray matter tissue from the dorsolateral prefrontal cortex (DLPFC) were sectioned while still frozen and shipped on dry ice overnight from the RADC to the Broad Institute. These sections were partially thawed on ice prior to dissection with a scalpel to separate the gray from the white matter and vasculature.
Between 50mg and 100mg of gray matter was then added to 1ml of Trizol and homogenized with a 5mm stainless steel bead for 30 seconds at 30 Hertz using the Qiagen TissueLyser II. Following a quick spin to settle the foam, we would invert the tube 2-3 times to observe if the sample was fully homogenized. If chunks of tissue were still observed the sample was put back in the TissueLyser for another round.
Homogenate was incubated at room temp for 5 minutes and then frozen at -80˚C.
Samples were later thawed and processed in batches of 12-24 samples for RNA extraction using the Qiagen MiRNeasy Mini (cat no. 217004) protocol, including the optional DNAse digestion step. This protocol yields total RNA that includes miRNA.
Samples were quantified by nanodrop and/or the RiboGreen assay; for each sample, the RNA Integrity Number (RIN) was measured using the Agilent Bioanalyzer Eukaryotic Total RNA Nano chip.
RNA Sequencing (RNA-Seq)
Samples were submitted to the Broad Institute's Genomics Platform for transcriptome library construction following the dUTP protocol 24 Recently, the data were reprocessed in parallel with other AMP-AD RNAseq datasets, and this second version of the data is available as well. The input data for the RNAseq reprocessing effort was aligned reads in bam files that were converted to fastq using the Picard SamToFastq function. Fastq files were re-aligned to the GENCODE24 (GRCh38) reference genome using STAR with twopassMode set as Basic. Gene counts were The miRNA from the Nanostring RCC files were re-annotated to match the definitions from the miRBase v19. The raw data from the Nanostring RCC files were accumulated and the probe-specific backgrounds were adjusted according to the Nanostring guidelines with the corrections provided with the probe sets. After correcting for the probe-specific backgrounds, a three-step filtering of miRNA and sample expressions was performed.
First, miRNA that had less than 95% of samples with a missing expression level were removed. This is followed by removing samples that had less than 95% of miRNAs with missing expressions. Thus, the call-rates for the samples and the miRNA are set at 95%.
Finally, all miRNA whose absolute value is less than 15 in at least 50% of the samples were removed to eliminate miRNA that had negligible expression in brain samples. After the miRNA and sample filtering, the dataset consisted of 309 miRNAs and 702 subjects.
A combination of quantile normalization and Combat 27 , specifying the cartridges as batches for the miRNA data, was used to normalize the data sets. Finally, uniquely mapped unique reads were extended towards their 3'-end to the estimated fragment size, and the number of reads overlapping each domain was computed for each sample. In total, read count data and bam files are available for 712 subjects.
DNA Methylation profile
As was done in the RNA extraction effort, gray matter was dissected from white matter while on ice from a sample of frozen DLPFC. This cortical sample was then processed using the Qiagen QIAamp mini protocol (Part number 51306) to extract DNA. Samples were evaporated to increase concentration to 50ng/ul and submitted to the Broad Institute's Genomics Platform for processing on the Illumina Infinium HumanMethylation450 BeadChip 28 .
Because of the use of different thermocyclers during data generation process, a strong batch effect was observed and we applied a series of strategies of quality control and data analysis to counter such batch effect. On the probe level QC, at first, we selected good quality probes according to the detection P value < 0.01 across all samples. We further removed those probes predicted to cross-hybridize with the sex chromosomes 29 and those having overlaps with known SNP with MAF ³0.01 (±10bp) based on the 1000 Genomes database. On the subject level QC, we at first used principal component analysis (PCA) based on 50,000 randomly selected probes to select subjects that were within ±3 s.d. from the mean of a principal component (PC) for PC1, PC2, and PC3.
Secondly, we filtered out those subjects with poor bisulfite conversion efficiency. We have compared data normalization strategy of COMBAT 27 β values reported by the Illumina platform were used as the measurement of methylation level for each CpG probe tagged on the chip. We imputed those missing β values using a k-nearest neighbor algorithm for k = 100. The primary data analysis includes adjustment of age, sex, and experiment batch variable. We estimated the proportion of NeuN+ cells (primarily neurons) in each brain sample using DNA methylation data 30 , but we did not find it had significant associations with a pathologic diagnosis of AD (P = 0.08). Overall, we have methylation profiles for 740 subjects.
Data Records
For high-dimensional data, the NIA-supported AMP-AD Knowledge Portal on the Synapse platform is the preferred distributor (Data Citation 1), and additional samples as well as phenotypic and other data are available through the RADC Research Resource Sharing Hub (Data Citation 2). Data from each unique participant is assigned the same 6 digit study ID, facilitating the relation of different data types. To download files see the 'How to Download' guide on the folder to download all folder content, and the Synapse documentation for more details: http://docs.synapse.org/articles/downloading_data.html.
The following are the key files: 
Technical Validation
Technical Validation:
Data derived based on DNA: Genotype, imputation, whole genome sequence, and methylation All DNA samples go through the same rigorous quality control process before and after genotype generation, so we see no difference in data quality based on source of DNA. Affymetrix GeneChip 6.0 platform and Illumina OmniQuad Express platform are well validated platforms for genotyping. Detailed QC pipeline was described in 12 . Briefly, the standard QC measures for SNPs (HWE p > 0.001; MAF > 0.01; genotype call rate > 0.95; misshap test > 1´ 10-9) and subjects (genotype success rate > 0.95; genotype-derived gender concordant with reported gender, excess inter/intra-heterozygosity) were applied. The top hits of the genotype data were successfully replicated in another independent dataset 12 . For the whole genome sequencing data, base quality score recalibration was performed using the GATK BQSR and the empirical calibration of the variant quality was done using GATK pipeline. Variants were further filtered for minimum read depth (DP), variant calling confidence score (QD), VQSLOD and mapping and variant quality scores (MQ, GQ). For the methylation data, we applied both probe-level (detection P ³ 0.01 across all samples; not cross-hybridize with the sex chromosomes; not overlapped with known SNPs with MAF ³ 0.01 within 10bp region) and subject-level QC (within 3 s.d. from the mean of a principal component (PC) for PC1, PC2 and PC3, and those with poor bisulfite conversion efficiency). The top hits were also successfully replicated in an independent sample 28 . Experimental replicates and controls were designed to calibrate data.
Data derived based RNA: RNAseq and miRNA
The RNA extraction protocol, Qiagen MiRNeasy Mini (cat no. 217004) protocol, has been validated to be effective to purify both total RNA and miRNA [31] [32] [33] [34] [35] [36] . For each sample, the RIN score was measured using the Agilent Bioanalyzer Eukaryotic Total RNA Nano chip. Those RNA samples with RIN score of 5 or better were submitted for cDNA library construction. RIN score affects the fragment lengths of RNA inserts for library construction, and therefore we batched samples according to RIN scores so that library pools would have uniform insert sizes. In order to get correct alignment, we trimmed the reads if they have low quality bases (Q10) from beginning and end or those reads of adapters and rRNA. Experimental replicates and controls were designed to calibrate data.
H3K9Ac ChIP-Seq Pooled DNA of 7 samples was used as negative control. A combination of five ChIP-seq quality measures were employed to detect low quality samples: samples that did not reach (i) ≥ 15´10 6 uniquely mapped unique reads, (ii) non-redundant fraction ≥ 0.3, (iii) cross correlation ≥ 0.03, (iv) fraction of reads in peaks ≥ 0.05 and (v) ≥ 6000 peaks were removed.
Usage Notes
All data are publically available following the completion of a data use agreement that can be completed through the RUSH University ADC (http://www.radc.rush.edu/requests.htm;jsessionid=A2587E2977951F15E7AEB2FF3812 F66A) or the Synapse platform (https://www.synapse.org/#!AccessRequirements:ID=syn3219045&TYPE=ENTITY).
The ROS and MAP cohorts have useful features that allow the data generated from their subjects to be repurposed for many different analyses and to render results relevant to the population of older individuals. Most importantly, all subjects are community-dwelling without known dementia at the time of enrollment. All testing is performed in the participants' homes, and the only inclusion criteria are age and willingness to sign the informed consent and Anatomical Gift Act. Thus, participants capture the full spectrum of phenotypes found in an aging human population. Further, both ROS and MAP include longitudinal rigorous clinical, functional, neuropsychologic and magnetic resonance imaging characterization of participants while they are alive, as well as a structured clinical and quantitative neuropathologic assessment at autopsy. The application of standard clinical scales to the collected data provide both syndromic diagnoses and semiquantitative measures such as the many cognitive function tests that allow the comparison of results from ROS and MAP to those from other collections of subjects. These simpler phenotypes also enables us to contribute data to consortia for joint or meta-analyses, as has been done for a wide range of clinical, imaging and pathologic phenotypes [37] [38] [39] . As clinical and pathologic phenotypes do not occur in isolation, the deep clinical and neuropathologic phenotyping of each subject enables investigators to resolve the contribution of a given molecular feature to multiple different intermediate traits that ultimately contribute to cognitive decline and other common conditions of aging.
We also note that certain limitations must be taken into account when interpreting results from these cohorts. (1) These cohorts sample a large spectrum of the older population but are not a random sample of the overall population; nonetheless, they capture a much larger spectrum of the aging population than most autopsy series that rely on the subset of individuals coming to the attention of the health care system because of their symptoms and often have highly selective recruitment criteria. (2) The mean age at study entry is 78.9 (SD=7.5, range 55.4-102.1), and the mean age at death is 89 (SD=6.6, range 65.9-108.3). Since subjects are older and without known demented at study entry, there is a bias in study entry stemming both from survival to older age from all causes of early mortality and from surviving to study entry without significant cognitive impairment. (3) The range of age at the time of death is broad but restricted to the older segment of the age distribution of the North American population. (4) Finally, agreement for organ donation likely introduces a subtle bias. However, it should be noted essentially all risk factors for AD dementia identified in the cohort have been replicated in other cohort studies.
We also note that many of these neuropsychologic and neuropathologic traits are correlated ( Table 4 ) and that many of these traits correlate with advancing age. The age and sex of subjects have very strong effects on the brain's epigenome and transcriptome; these two variables are important confounders when performing any analyses of ROS and MAP data. Further, one must carefully consider the molecular effects of neuropathologies that confound aging-related analyses as we have shown with the methylome 40 . Finally, both circadian and seasonal rhythms influence the epigenome and the transcriptome, introducing an important source of variation for many genes that is rarely appreciated 41 .
The ROS and MAP cohorts have been designed for data and sample sharing, and they have been at the forefront of large-scale omic data generation from the human brain and also of sharing such data through efforts such as the DREAM challenge 5 and the AMP-AD research program funded by the National Institute of Aging. The data described in this report represent data that exist today and are available on Synapse. Numerous additional layers of data, including proteomic and metabolomic data, from tissue samples and purified cell populations are being produced and will become available as the data are finalized. We look forward to this large set of molecular and phenotypic data being repurposed by the neuroscience and other communities of researchers. A widely used, 30 item, standardized screening measure of dementia severity.
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Assessment of neuritic plaques A semiquantitative measure of neuritic plaques and the diagnosis includes algorithm and neuropathologist's opinion.
Final clinical consensus diagnosis
At the time of death, all available clinical data were reviewed by a neurologist with expertise in dementia, and a summary diagnostic opinion was rendered regarding the most likely clinical diagnosis at the time of death. Summary diagnoses were made blinded to all postmortem data. Case conferences including one or more neurologists and a neuropsychologist were used for consensus on selected cases. Age at death 1.0
